SITC 2017 Abstract Titles – Mechanisms of Efficacy or Toxicity

#

Title

Authors

Affiliations

Keywords

P372

A syngeneic mouse model of CAR-T mediated toxicity and neuroinflammation

Eric Chadwick¹, Alyssa Noll¹, Yue Jiang¹, Ronald Hause¹, Rafael Ponce¹, Hyam Levitsky¹, Ruth Salmon¹

¹Juno Therapeutics, Seattle, WA, USA

Inflammation | Immune toxicity | CAR T cells | Gene expression | Leukemia/Lymphoma

P373

Optimizing anti-OX40 mediated immunotherapy: preclinical exploration of the relationship between antitumor activity and isotype choice, ligand blocking capacity, dose and schedule

Chan Gao¹, John Engelhardt², Gennaro Dito¹, Susan Glick¹, Megan Raymond¹, Marie-Claude Gaudreau¹, Alan Korman², Michael Quigley¹

¹Bristol-Myers Squibb, Princeton, NJ, USA ²Bristol-Myers Squibb, Redwood City, CA, USA

T cell | Checkpoint blockade | Costimulation | Regulatory T cell (Treg)

P374

Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway

Ashvin R. Jaiswal¹, Todd Bartkowiak¹, Casey R. Ager¹, Renee Chin¹, Chao-Hsien Chen¹, Pratha Budhani¹, Midan Ai¹, Matthew J. Reilley¹, Manu M. Sebastian², David S Hong¹, Michael A Curran¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA ²The University of Texas MD Anderson Cancer Center, Smithville, TX, USA

Costimulation | Myeloid cells | Checkpoint blockade | Immune toxicity | Cytokine | Chemokine | Immune suppression | T cell

P375

Evaluation of surrogate endpoints for overall survival in patients treated with immunotherapies

Howard Kaufman¹, Lawrence Schwartz², William William³, Mario Sznol⁴, Michael del Aguila⁵, Craig Whittington⁵, Kyle Fahrbach⁶, Yingxin Xu⁶, Eric Masson⁷, Andrea Vergara-Silva⁸

¹Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA ²Columbia University Medical Center, New York, NY, USA ³MD Anderson Cancer Center, Houston, TX, USA ⁴Yale School of Medicine, New Haven, CT, USA ⁵Doctor Evidence, Santa Monica, CA, USA ⁶Evidera, Bethesda, MD, USA ⁷AstraZeneca, Waltham, MA, USA ⁸AstraZeneca, Gaithersburg, MD, USA

Checkpoint blockade | Chemotherapy | Targeted therapy

P376

Evaluating CD38 as a Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Michelle Kinder¹, Mark Mendonca¹, Khaja Syed¹, Melissa Parker¹, Patrick Wilkinson¹, Edward Thompson¹, Gerald Chu¹, Christopher Chiu¹, Natalie Hutnick¹

¹Janssen Research and Development, LLC, Spring House, PA, USA

Antibody | Gene expression | MDSC | Solid tumors | Regulatory T cell (Treg) | Targeted therapy | Tumor infiltrating lymphocytes (TILs)

P377

Cisplatin Induces Immunogenic Cell Death in Preclinical Models of Head and Neck Squamous Cell Carcinoma

So-Jin Park¹, Linda Tran¹, Roy Xiao^1,2, Carter Van Waes¹, Nicole Schmitt^1,3

¹NIDCD, NIH, Bethesda, MD, USA ²Cleveland Clinic Lerner College of Medicine, Bethesda, MD, USA ³Johns Hopkins University, Bethesda, MD, USA

Chemotherapy | Tumor microenvironment | Checkpoint blockade

P378

Improving the efficacy of cancer immunotherapy: An intimate play of CD8T and NK cells

Roman Uzhachenko¹, J Shawn Goodwin¹, William Hofmeister², Anil Shanker^1,3

¹Meharry Medical College School of Medicine, Nashville, TN, USA ²University of Tennessee Space Institute, Tullahoma, TN, USA ³Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Adoptive immunotherapy | Tumor microenvironment | Tumor evasion | Tumor infiltrating lymphocytes (TILs) | Solid tumors | NK/NK T cell | T cell

P379

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Spencer Wei¹, Jacob Levine², Alexandria Cogdill¹, Yang Zhao¹, Nana-Ama Anang¹, Miles Andrews¹, Padmanee Sharma¹, Jing Wang¹, Jennifer Wargo¹, Dana Pe'er², James Allison¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA ²Sloan Kettering Institute, New York, NY, USA

T cell lineages | Systems biology | Bioinformatics | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Costimulation

P380

The Role of Radiotherapy in Driving Anti-Tumor CD8 T Cell Responses

Lauren Zebertavage¹, Alejandro Alice², Marka Crittenden², Michael Gough²

¹Oregon Health and Science University, Portland, OR, USA ²Earle A Chiles Research Institute, Portland, OR, USA

Radiotherapy | Solid tumors | T cell | Checkpoint blockade | Vaccine